Siegfried Holding AG Share Price London S.E.

Equities

0QQO

CH0014284498

Pharmaceuticals

Real-time Estimate Cboe Europe 09:07:10 31/05/2024 BST 5-day change 1st Jan Change
873 CHF -1.02% Intraday chart for Siegfried Holding AG -1.67% +2.48%

Financials

Sales 2024 * 1.3B 1.44B 113B Sales 2025 * 1.42B 1.57B 124B Capitalization 3.77B 4.17B 328B
Net income 2024 * 148M 164M 12.88B Net income 2025 * 172M 190M 14.96B EV / Sales 2024 * 3.17 x
Net Debt 2024 * 351M 388M 30.52B Net Debt 2025 * 313M 346M 27.27B EV / Sales 2025 * 2.88 x
P/E ratio 2024 *
25.4 x
P/E ratio 2025 *
21.9 x
Employees 3,945
Yield 2024 *
0.44%
Yield 2025 *
0.46%
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.02%
1 week-1.67%
3 months-2.54%
6 months+11.87%
Current year+2.48%
More quotes
1 week
873.00
Extreme 873
891.00
1 month
844.00
Extreme 844
903.00
Current year
828.00
Extreme 828
947.50
1 year
657.50
Extreme 657.5
947.50
3 years
566.50
Extreme 566.5
947.50
5 years
316.50
Extreme 316.5
947.50
10 years
137.49
Extreme 137.4855
947.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 30/04/17
Chief Tech/Sci/R&D Officer 56 31/03/19
Corporate Officer/Principal - 31/01/14
Members of the board TitleAgeSince
Director/Board Member 55 31/12/15
Director/Board Member 63 31/12/13
Chairman 61 31/12/09
More insiders
Date Price Change Volume
30/04/24 882 +26.36% 25
30/05/24 880 +0.46% 205
29/05/24 876 -0.34% 175
28/05/24 879 0.00% 218
27/05/24 879 -0.57% 122

Delayed Quote London S.E., April 30, 2024 at 04:40 pm

More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
880 CHF
Average target price
1,016 CHF
Spread / Average Target
+15.44%
Consensus